as of 02-05-2026 11:10am EST
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
| Founded: | 2008 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 12.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 186.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.89 - $7.64 | Next Earning Date: | 12-01-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -689876.0 | FCF Growth: | N/A |
See how NCEL stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "NCEL NewcelX Ltd. Ordinary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.